• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Immunogenicity of the Trivalent Inactivated Influenza Vaccine in Young Children Less Than 4 Years of Age: Focus on Age and Baseline Antibodies

tetano

Editor, Senior Moderator
Clin Vaccine Immunol. 2014 Jul 2. pii: CVI.00200-14. [Epub ahead of print]
Immunogenicity of the Trivalent Inactivated Influenza Vaccine in Young Children Less Than 4 Years of Age: Focus on Age and Baseline Antibodies.
Mugitani A1, Ito K2, Irie S3, Eto T4, Ishibashi M4, Ohfuji S5, Fukushima W5, Maeda A5, Hirota Y6; the Fukuoka Pediatricians Group for Vaccine Efficacy.
Author information
Abstract

In this study, we assessed the effects of the pre-vaccination titer and age on the immunogenicity of a low dose of influenza vaccine in children less than 4 years of age. A total of 259 children received two vaccine doses (0.1 ml for 0-year-olds and 0.2 ml for children 1 year of age or older) four weeks apart during the 2005/2006 season. The hemaggulutination inhibition antibody titers were measured before vaccination and four weeks after the first and second dose. The geometric mean titer, mean fold rise, seroresponse proportion (≥4-fold rise in titer) and seroprotection proportion (titer≥1:40) were calculated for the pre-vaccination titer and age categories. A multivariate logistic regression analysis was performed using the seroresponse and seroprotection proportions as dependent variables and the pre-vaccination titer and age as explanatory variables. As for the seroresponse against H1 antigen after the first dose, the adjusted odds ratio of the pre-vaccination titers (vs. <1:10) was 2.2 (95% confidence interval: 0.8-5.8) at 1:10 to 1:20 and 0.14 (0.04-0.49) at ≥1:40. The corresponding figures for ages were 0.03 (0.01-0.07) for the 0-year-olds and 0.17 (0.08-0.34) for the 1-year-olds compared with the 2- to 3-year-olds (trend P<0.001). Similar results were also obtained for the H3 and B strains. Significantly elevated odds ratios for seroprotection were observed, with greater pre-vaccination titers and older ages, for all strains. The pre-vaccination titer and age were independently associated with the antibody response in young children. The immune response was weaker in the younger children and those without preexisting immunity.

Copyright ? 2014, American Society for Microbiology. All Rights Reserved.

PMID:
24990904
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24990904
 
Back
Top Bottom